DIMERIX EXPANDS PIPELINE WITH ACQUISITION OF PHASE 2 READY ASSET FOR ACUTE KIDNEY INJURY
The acquisition adds an oral small molecule with Phase 1 safety data and a planned study in about 160 post-cardiac surgery patients.
- On Friday, July 17, 2026, Dimerix Limited acquired the Phase 2-ready drug candidate DMX-652 from Mission Therapeutics Limited, expanding its renal-focused pipeline into acute kidney injury treatments.
- Acute kidney injury represents a significant clinical burden with a global market opportunity estimated at US$3.5 billion in 2026, yet no therapies are currently approved to treat the condition, which causes rapid kidney function decline.
- As a first-in-class small molecule, DMX-652 inhibits USP30 to support mitochondrial quality in injured kidney cells, with a Phase 1 trial of 85 healthy participants demonstrating the drug was well tolerated at various doses.
- Dimerix confirmed it is fully funded through completion of the ACTION3 Phase 3 trial for its lead asset, DMX-200, as well as initiation of the Phase 2 clinical trial in DMX-652 through existing cash reserves and binding loan agreements.
- A planned multicentre study will evaluate DMX-652 in approximately 160 patients at high risk of AKI following cardiac surgery, with an interim data readout anticipated during 2027 to assess safety and efficacy.
11 Articles
11 Articles
PR Newswire
FNArenaDIMERIX EXPANDS PIPELINE WITH ACQUISITION OF PHASE 2 READY ASSET FOR ACUTE KIDNEY INJURY
Highlights Dimerix acquires Phase 2-ready asset, DMX-652 - with potential for rapid advancement into a Phase 2 clinical study under an open US Investigational...
The Norfolk Daily News
Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline
Mission Therapeutics has divested MTX652, a Phase 2-ready selective USP30 inhibitor for Acute Kidney Injury (AKI), to
Dimerix acquires Phase 2-ready asset for acute kidney injury - BioTuesdays
Dimerix (ASX: DXB) has announced that it has acquired DMX-652 for all indications from closely held Mission Therapeutics, expanding its pipeline in rare kidney disease. DMX-652 is a novel first and best-in-class therapeutic candidate, initially targeting the prevention of acute kidney injury. According to Dimerix, its unique mechanism of action may allow it to be progressed into other indications. In a statement, Dr. Nina Webster, CEO and managi…
Mission Therapeutics refocuses on CNS and sells $292M kidney drug to Dimerix - European Biotechnology Magazine
UK biotech Mission Therapeutics has sold its Phase 2-ready acute kidney injury drug MTX652 to Australia’s Dimerix in a deal worth up to $292 million (€254.7 million), freeing Mission to concentrate resources on its central nervous system (CNS) pipeline. The post Mission Therapeutics refocuses on CNS and sells $292M kidney drug to Dimerix appeared first on European Biotechnology Magazine.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
